Pall Onundarson: Diluted Fiix Test Can Be Used to Measure DOACs
Pall Onundarson, Professor Emeritus at Landspitali University Hospital, shared on LinkedIn:
”Diluted Fiix test (dFiix-PT) can be used to measure DOACs.
DOACs were developed to replace VKAs, which were considered difficult to manage because of fluctuating anticoagulant effect measured as PT-INR, commonly attributed to food and drug interactions.
Few considered that the measurement tool itself, the prothrombin time, might have an inherent flaw contributing to variability and amplifying need for dose adjustments.
About 20 years ago, coagulation experts at TandH meetings repeatedly expressed skepticism that oral anticoagulants should be used without monitoring or tailoring.
Nevertheless, DOAC manufacturers conducted RCTs comparing unmonitored DOACs with, in many cases, poorly monitored warfarin, aiming to replace cheap old warfarin entirely.
When results were favorable, DOACs – supported by many key opinion leaders -became first-line for non-valvular AF and most VTE patients and were reimbursed despite higher costs.
At the same time, potential major improvements in warfarin management, such as newer monitoring methods, were largely ignored.
PT-monitored warfarin nevertheless persisted, as it gradually proved superior to DOACs in certain high-risk conditions and remained cheaper, even when monitoring costs were included.
More recently, the need to measure DOAC levels has gained attention, with multiple semi-quantitative and quantitative wet-lab and POC assays described, most far more expensive than the old PT-INR, further increasing DOAC costs.
As many of my LinkedIn contacts know, the Fiix test stabilizes warfarin and appears to reduce thromboembolism substantially compared with PT-INR–monitored warfarin, with proportionally greater benefits than those reported for DOACs versus PT-warfarin.
Our studies have been limited by the small Icelandic population and funding, but Fiix has now shown measurement superiority at a major UK center (personal communication), and a large independent RCT comparing Fiix-warfarin to PT-warfarin in MHV patients is being prepared in North America.
Less well known is that a diluted Fiix test (dFiix-PT), and – less optimally – diluted PT (dPT), can assess DOAC concentrations.
Thromboplastin dilution enhances sensitivity to DOACs and heparins, enabling an inexpensive, easily implemented semi-quantitative DOAC assay, demonstrated and published by us 10 years ago (Loic Leterte et al, see headshot).
Would anyone be interested in a cheap DOAC assay applicable to coagulometers?”
Stay updated with Hemostasis Today.
-
Oct 30, 2026, 16:44Shehab Mohamed: Recognizing Isolated Thrombocytopenia as a Presentation of MDS
-
Oct 30, 2026, 16:40Amrita Sarkar: Advancing the Diagnosis of Anti-PF4 Syndromes
-
Oct 30, 2026, 16:35James Garrard: Driving Innovation in Stroke Care Through Global Collaboration
-
Oct 30, 2026, 16:19Cesar de Almeida Neto: Hemo 2026 Roundtable Focuses on the Challenges of Patient Blood Management
-
Oct 30, 2026, 16:01Marilena Vrana: The Case for Retaining Immunoglobulins on the EU Critical Medicines List
-
Oct 30, 2026, 15:53Ilenia Calcaterra: Patient Blood Management Across Complex Hematological Conditions
-
Oct 30, 2026, 15:40Isabella Presch: The Practicalities of Gene Therapy Adoption in Hemophilia
-
Oct 30, 2026, 15:12Edward C.C. Wong: Navigating the Implications of the 2026 ASH Guidelines for Blood Donation
-
Oct 30, 2026, 14:53Pall T. Onundarson: Anticoagulation Guidelines Under the Influence of Pharmaceuticalisation